Drug news

Teva Pharmaceutical Industries will market Adasuve for treatment of agitation in Schizophrenia in the United States

Read time: 1 mins

Last updated:9th May 2013

Published:9th May 2013

Source: Pharmawand

Alexza Pharmaceuticals, Inc. announced that they have entered into an exclusive U.S. license and supply agreement with Teva Pharmaceutical Industries Ltd for Adasuve (Staccato loxapine).

Adasuve is Alexza's first approved product and was approved by the FDA in December 2012 and by the European Medicines Agency in February 2013. Teva Pharmaceutical USA Inc. is Alexza's commercial partner for Adasuve in the U.S. Grupo Ferrer Internacional, S.A. is Alexza's commercial partner for Adasuve in Europe, Latin America, Russia and the Commonwealth of Independent States countries/

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Click here to view

Related news and insights

Drug news

The FDA has approved the Esprit BTK Everolimus Eluting Resorbable Scaffold System (Esprit BTK System), a breakthrough innovation for people with chronic limb-threatening ischemia below-the-knee

Abbott announced that the FDA has approved the Esprit BTK Everolimus Eluting Resorbable Scaffold System (Esprit BTK System), a breakthrough innovation for people with chronic limb-threatening ischemia (CLTI) below-the-knee (BTK)

2 mins

Drug news

Promising findings in phase IIb/III clinical trial of NRX 101 vs. lurasidone for treatment of suicidal bipolar depression

NRx Pharmaceuticals, Inc. announced that its Breakthrough Therapy designated investigational drug NRX 101 vs lurasidone demonstrated a promising, though not yet statistically significant 33% reduction in suicidality together with a 70% reduction (P=.076) reduction in symptoms of akathisia – a side effect of antidepressants that is closely linked to suicide and considered a medical emergency

1 min

Drug news

FDA approval of Ingrezza Sprinkle (valbenazine) capsules for the treatment of adults with tardive dyskinesia and chorea associated with Huntington's disease

Neurocrine Biosciences, Inc. announced the FDA has approved Ingrezza Sprinkle (valbenazine) capsules, a new oral granules formulation of Ingrezza (valbenazine) capsules prescribed for the treatment of adults with tardive dyskinesia and chorea associated with Huntington's disease

1 min

See all news